- Home
- LEE vs IGC Comparison
LEE vs IGC Comparison
Compare LEE & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEE
- IGC
- Stock Information
- Founded
- LEE 1890
- IGC 2005
- Country
- LEE United States
- IGC United States
- Employees
- LEE N/A
- IGC N/A
- Industry
- LEE Newspapers/Magazines
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- LEE Consumer Discretionary
- IGC Health Care
- Exchange
- LEE Nasdaq
- IGC Nasdaq
- Market Cap
- LEE 42.1M
- IGC 39.8M
- IPO Year
- LEE N/A
- IGC N/A
- Fundamental
- Price
- LEE $4.22
- IGC $0.42
- Analyst Decision
- LEE
- IGC Strong Buy
- Analyst Count
- LEE 0
- IGC 2
- Target Price
- LEE N/A
- IGC $4.00
- AVG Volume (30 Days)
- LEE 27.5K
- IGC 1.4M
- Earning Date
- LEE 08-07-2025
- IGC 08-14-2025
- Dividend Yield
- LEE N/A
- IGC N/A
- EPS Growth
- LEE N/A
- IGC N/A
- EPS
- LEE N/A
- IGC N/A
- Revenue
- LEE $581,809,000.00
- IGC $1,327,000.00
- Revenue This Year
- LEE N/A
- IGC $15.26
- Revenue Next Year
- LEE N/A
- IGC $3.41
- P/E Ratio
- LEE N/A
- IGC N/A
- Revenue Growth
- LEE N/A
- IGC 24.95
- 52 Week Low
- LEE $3.79
- IGC $0.25
- 52 Week High
- LEE $19.63
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- LEE 43.89
- IGC 56.28
- Support Level
- LEE $3.82
- IGC $0.39
- Resistance Level
- LEE $4.44
- IGC $0.47
- Average True Range (ATR)
- LEE 0.24
- IGC 0.04
- MACD
- LEE 0.07
- IGC 0.00
- Stochastic Oscillator
- LEE 58.84
- IGC 46.67
About LEE Lee Enterprises Incorporated
Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.